US › Healthcare

Opus Genetics, Inc. (IRD)

US · Healthcare · Biotechnology

$3.71+1.92%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.2M
Revenue YoY
-50.6%
Net profit
$-65.5M
Profit YoY
-699.8%
EPS
$-0.75
EPS estimate
$-0.14
Net margin
-3,038.2%

EPS came in at -0.75 against a street estimate of -0.14 — a miss of 435.7%.

Key statistics

Market cap
$306.3M
Forward P/E
12.0
P/B
23.82
Book value
$-0.64
EPS (TTM)
$-1.31
52-week high
$5.81
52-week low
$1.04
50-day MA
$3.87
200-day MA
$3.46
Beta
0.56

Analyst view

Analysts rate Opus Genetics, Inc. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $10.56.

Shareholding

Insiders
11.03%
Institutions
55.71%

Largest institutional holders

FundStake
Caligan Partners LP7.36%
Adage Capital Partners Gp LLC7.30%
BIOS CAPITAL MANAGEMENT, LP4.46%
Balyasny Asset Management LLC3.29%
Millennium Management LLC3.19%
Vanguard Capital Management, LLC2.97%
Marshall Wace Asset Management Ltd2.80%
Boxer Capital Management, LLC2.73%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Opus Genetics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.